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Abstract
Accurate identification of intermediate risk (Gleason 31 45 7) prostate cancer patients with low risk of dis-
ease progression is an unmet challenge in treatment decision making. Here we describe a gene signature that
could guide clinicians in the selection of patients with intermediate stage clinically localized prostate cancer
for active surveillance. We examined six major drivers of aggressive disease – PTEN, MYC, RB1, TP53, AURKA,
AR – by immunohistochemistry in a focused (N5 69) cohort predominantly consisting of intermediate risk
prostate cancer. Fuzzy clustering and unsupervised hierarchical clustering were utilized to determine the corre-
lation of gene expression and methylation values with immunohistochemical expression. From the immunohis-
tochemistry observation, we found that intermediate risk prostate cancer cases could be classified as ‘complex’
(differential expression of more than one driver) or ‘simple’ (differential expression of only one). Focussing on
the ‘simple’ cases, expression and methylation profiling generated signatures which correlated tightly only
with differential PTEN expression and not with any of the other drivers assessed by immunohistochemistry.
From this, we derived a geneset of 35 genes linked to high PTEN expression. Subsequently we determined its
prognostic significance in intermediate-risk cases extracted from three publicly available clinical datasets
(Total N5 215). Hence, this study shows that, by using immunohistochemistry as an upfront stratifier of
intermediate risk prostate cancers, it is possible to identify through differential gene expression profiling a
geneset with prognostic power across multiple cohorts. This strategy has not been used previously and the sig-
nature has the potential to impact on treatment decisions in patients for whom decision making is currently
empirical at best.
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Introduction
Prostate cancer remains the second most common
cancer-related death for men in developed nations [1].
In the United Kingdom, prostate cancer has become
the most common form of cancer in males, surpassing
lung and bowel cancers [2]. This is attributed to pop-
ulation aging in the region and the prevalent use of
prostate-specific antigen as a screening biomarker [3].
Despite increased understanding of prostate cancer
biology, the current standard of care is still dependent on
the Gleason score of the patient’s tumour [4]. In general,
most prostate tumours are low and intermediate grades
(Gleason score 6 and 7). To prevent overtreatment, there
has been an emerging approach of non-treatment or
active surveillance for patients who present with tumours
graded lower than Gleason score 7. Here the intent to
prevent overtreatment could obscure the opportunity for
early intervention, especially in potentially fast-growing
and aggressive tumours. Thus, molecular genomic analy-
sis may be useful in identifying such potentially aggres-
sive tumours that cannot be distinguished by existing
practices.
Several studies have utilized next-generation high-
throughput methodologies to characterize the differ-
ent molecular genomic aberration events in prostate
cancer. These studies have collectively shown that
the most frequent genomic events in prostate cancer
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are the amplification or mutation of the androgen
receptor, loss of the PTEN tumour suppressor gene,
and the genomic rearrangement events surrounding
the oncogenic transcription factor ERG. Particularly,
loss of PTEN was associated with advanced stage
and poor prognosis in prostate cancer [5–9]. These
studies have allowed researchers to understand each
major genomic aberration involved in prostate cancer
development and progression.
Despite understanding the various genomic events
in prostate cancer, the molecular characterization of
cancer subtypes by genomic analysis is more success-
ful and widespread in other cancer types, such as
breast and colorectal cancers [10–13]. It is only in
recent years that genomic profiling has been employed
in a therapeutic setting in prostate cancer, giving rise
to a number of commercially available transcript sig-
natures that are now being used as clinical nomograms
to predict disease outcome (Prolaris, Oncotype DX
Genomic Prostate Score, and Decipher) [14–16]. All
three assays are primarily designed and used in the
setting of diagnostic biopsies for advanced prostate
cancers, but occasionally are also used in intermediate
risk prostate cancer. The Prolaris genomic assay
(Myriad Genetics, UT, USA) is a 46-gene expression
panel that encompasses mostly cell-cycle progression
genes that improves prediction of metastatic progres-
sion risk in men undergoing external beam radiation
after radical prostatectomy [14]. Similarly, the 22-gene
Decipher genetic test (GenomeDX Biosciences,
Vancouver, Canada) [16] is reported to enhance pre-
diction of metastatic progression risk in men under-
going External Beam Radiation Therapy [17] as well
as prostate cancer-specific mortality [18]. Conversely,
the 17-gene Oncotype DX Genomic Prostate Score
assay (Genomic Health Inc., CA, USA) [15] is
reported to be significantly associated with adverse
pathological features as well as time to metastasis
[19]. Except for one common gene between the Prola-
ris and Decipher assay, there are no overlapping genes
reported between these three gene-expression-based
tests. These tests correlate to some degree with high
grade, high stage disease. Thus, in-depth molecular
characterisation of the most demanding clinical risk
group for prostate cancer, intermediate risk disease,
may aid in the further stratification of patients. This
can determine who might benefit from early treatment
intervention provided that it is possible to subdivide
these cases in some manner prior to transcript or
methylation profiling.
Here, we systematically profiled a small cohort of
radical prostatectomy cases consisting almost entirely
of intermediate risk, Gleason 7 (31 4), disease.
Using an initial immunohistochemical analysis of
defined genetic markers, followed by subsequent
gene expression, and methylation profiling of the
samples, we have integrated this data to derive a 35-
geneset which is prognostic in single grade disease
across multiple cohorts.
Patients and methods
Patient datasets
For this study, the main clinical cohort is referred to
as the Northern Ireland dataset (N5 62). Ethical per-
mission for the study was granted by the Northern
Ireland Biobank (Ethics: 11/NI/0013/NIB13–0074).
The clinical features of this cohort are described in
supplementary material, Table S1. For validation of
the gene expression signature, the datasets used are
referred as the Taylor dataset (GSE21032), the
Sboner dataset (GSE16560), and the Gulzar dataset
(GSE40272) [20–22]. All selected cases were
assigned a combined Gleason score of 31 4. Gleason
41 3 cases were excluded. Both Taylor and Gulzar
cohorts were radical prostatectomy specimens. The
Sboner cohort comprised transurethral resection
specimens. Overall survival was used as the outcome
measure for the Taylor cohort. Recurrence free sur-
vival was used as the outcome measure for the Gul-
zar and Sboner cohort (supplementary material, Table
S2). A total of 28 cases from the Northern Ireland
dataset were analysed for gene expression, methyla-
tion, and mutations (Figure 1). These cases were
selected based on immunohistochemical expression
and belonged to the ‘simple’ subgroup (or cases asso-
ciated with abnormal expression of only one marker)
as outlined in Figure 2.
Patient specimens and nucleic acid extraction
Formalin-fixed and paraffin-embedded (FFPE) radical
prostatectomy tissue specimens were obtained from
the Northern Ireland Biobank constituting the NI
Dataset. Sequential 4 lm sections of each case were
sectioned and placed on glass slides (a total of 20
lm). Tumour regions were macro-dissected into ster-
ile 1.5 ml Eppendorf tubes. RNA was extracted using
the Qiagen RNAeasy kit (Qiagen GmbH, Hilden,
Germany). Genomic DNA was extracted using the
Promega Genomic DNA extraction kit (Promega, WI,
USA). All standard procedures were in accordance
with the manufacturer’s protocols. Extracted DNA
and RNA were quantified and assessed for their qual-
ity using Agilent Bioanalyser chips (Agilent Technol-
ogies, CA, USA).
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Tissue microarray (TMA) construction and
immunohistochemistry (IHC)
For the construction of tissue microarrays, representa-
tive FFPE tissues from selected resection materials
were cored (0.6 mm) and arrayed into a donor recipi-
ent block using a tissue microarrayer (Beecher Instru-
ments, WI, USA). Consecutive TMA paraffin
sections of 4 lm thickness were cut and placed onto
silanated slides for immunohistochemical detection.
Immunohistochemistry was performed for AR,
AURKA, ERG, MTOR, P53, PTEN, and RB1. Stand-
ard processing steps for each antibody were in
accordance with manufacturer’s instructions. In brief,
heat-induced antigen retrieval with epitope retrieval
ER1 solution (Leica Biosystems, Newcastle, UK)
was performed for 20 min prior to incubation with
primary antibody. Slides were incubated with primary
antibody at optimized concentration. After incuba-
tion, slides were washed with Bond washing buffer
(Leica Biosystems) and incubated with secondary
antibody (Bond Polymer Refine kit; Leica Biosys-
tems). Subsequently chromogenic detection was
achieved by incubation with 3,30-diaminobenzidine
(DAB) followed by Bond DAB enhancer (Leica Bio-
systems). All slides were counterstained with haema-
toxylin and dehydrated through ascending ethanol to
xylene before mounting. Further details regarding the
use of each commercially available antibody includ-
ing the dilution used are described in supplementary
material, Table S3.
Scoring criteria for immunohistochemistry
expression
A modified Allred scoring method was utilized for
evaluating the immunohistochemical expression of
each marker [23]. First, intensity and proportion of
positive immunoreactivity of each marker were eval-
uated in each core without knowledge of the clinico-
pathological information. The staining intensity of
each marker was scored as 0 (negative), 11 (weak),
21 (moderate), and 31 (strong) while the proportion
of positive immunoreactivity was scored in percen-
tages. Subsequently, a dichotomous expression score
was obtained by considering both the staining inten-
sity and the proportion of stained cells within each
core (supplementary material, Table S4). In brief, the
intensity was scored as ‘low expressing’ (no or low
staining in less than 50% of cells) or ‘high express-
ing’ (moderate or intense staining in more than 50%
of cells). The majority expression scores were then
taken as the overall score. Each TMA was analysed
and scored by three observers independently (CWO,
SM, and MST).
Figure 1. Flowchart outlining the workflow and patient selection for determining the prognostic ability of the gene signature in Glea-
son 7 (31 4) patients.
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In view of the importance of PTEN after the initial
analysis of results, a thorough validation of PTEN
analysis at all levels was carried out in parallel while
delivering the results of this study [24].
Whole genome gene expression
Whole genome gene expression analysis was per-
formed using the Illumina (Illumina, CA, USA) WG-
DASL assay in accordance with the manufacturer’s
protocol. In brief, 100 ng of FFPE RNA was con-
verted to cDNA by the WG-DASL assay using biotin-
tagged random nonamer and oligo (dT) primers. The
biotinylated cDNA was then mounted onto a
streptavidin-coated support and further extended and
ligated by gene-specific oligonucleotides. Subse-
quently, polymerase chain reaction (PCR) amplifica-
tion was performed. The resulting PCR products were
eluted and hybridized to the Illumina Human-Ref v3.0
Beadchip and scanned with the Illumina iScan Reader
(Illumina). The image intensity values from the
microarray images generated were then analyzed using
the GenomeStudio Gene Expression Module (Illu-
mina) software. The processed expression values were
subsequently used for further analysis in this study.
Whole genome methylation
Whole genome methylation analysis was performed
using the Illumina Infinium HD (Illumina) assay in
accordance with the manufacture’s protocol. In brief,
1000 ng of genomic DNA extracted from the FFPE
samples was firstly treated with sodium bisulphite
to convert unmethylated cytosines to uracils. The
bisulphite-treated DNA was denatured and isother-
mally amplified overnight. After amplification, post-
amplified DNA was fragmented using a proprietary
enzymatic process and precipitated using isopropanol.
Precipitated DNA was collected by centrifugation
and re-suspended in a hybridization buffer, prior to
hybridisation onto the Infinium 450K Beadchip (Illu-
mina). The loaded chip underwent further extension
Figure 2. (A) Representative immunohistochemical expression of the markers utilized in the selection of cases for high-throughput
analysis. Bar charts adjacent to each marker describe the dichotomized expression frequencies (0, 11 versus 21, 31) of the corre-
sponding marker. (B) Diagram describing the sample selection criteria for high-throughput analysis. The patients (N5 62) were
aligned according to the number of genomic aberrations present, in ascending order. A total of 28 cases were chosen on the basis
that they each represent a single biomarker aberration based on their immunohistochemical expression. HT, high throughput.
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and staining steps. Subsequently, the Illumina iScan
reader was used to derive image intensity values
from the stained chip using the high-resolution scans
of the chip. The image intensity values were proc-
essed and normalized using the GenomeStudio Gene
Expression Module (Illumina). The processed methyl-
ation values were subsequently used for further anal-
ysis in this study.
Cancer gene-targeted next-generation DNA
sequencing
The Ion Ampliseq (Life Technologies, Carlsbad, CA,
USA) assay simultaneously amplified 50 oncogenes
and tumour suppressor genes covering 2800 COS-
MIC mutations in a single-tube reaction. A minimum
of 50 ng of FFPE DNA was used for molecular
profiling according to the manufacturer’s instructions
with the Ion PGM system. In brief, the pooled DNA
was paired and amplified with Ion Torrent adapters
to produce a DNA template library. The resulting
library then underwent sample emulsion PCR in
which copies of the DNA template were allowed to
amplify in the Ion Sphere Particles (ISP). Subse-
quently, the ISPs were recovered and barcoded. Next,
barcoded samples were sequenced on the Ion Torrent
PGM for 65 cycles, as per the recommended proto-
col. Finally, the resulting data were analysed for sin-
gle nucleotide polymorphism by the proprietary
Variant Caller Plugin within the Ion Torrent software
suite (Life Technologies).
Cluster analysis of gene expression and
methylation data
For the 28 cases interrogated from the Northern
Ireland dataset, raw intensity data from gene expres-
sion and methylation data were exported from
GenomeStudio software (Illumina) and Log2 trans-
formed for cluster analysis. The nonnegative matrix
factorisation (NMF) package for the R statistical soft-
ware was used for the cluster analysis of the whole
genome gene expression and methylation values [25].
The NMF method allowed identification of clusters
in an unsupervised manner based on the Euclidean
distance and average linkage. This was performed
over genes with highest variation across patients.
Risk stratification analysis
To assess the prognostic performance of the gene sig-
nature after identification, a prognostic index based
on SurvExpress was used [26]. This prognostic index
is the linear component of the exponential function
used to measure the level of association of the gene
signature in a Cox proportional hazards model. More
specifically, the prognostic index can be calculated
as: PI 5 b1v11 b2v21. . .1 bpvp in which v1 refers
to the expression value of Gene1 and bi refers to the
risk coefficient obtained from the Cox modelling.
The median value (PI5285.4) of the prognostic
index for the training cohort (GSE21032) was then
used to stratify risk groups. In subsequent analysis,
high risk cases were cases with a prognostic index
above the determined median value. Gene expression
data and associated clinical parameters deposited at
Gene Expression Omnibus were downloaded for
GSE21032, GSE16560, and GSE40272 [20–22] and
evaluated using the SurvExpress prognostic index.
Survival analysis
For graphical representation of the difference in sur-
vival outcome between risk groups for each dataset,
the Kaplan–Meier method was used with differences
assessed by the log-rank method. 10-year recurrence-
free survival (any recurrence, or death from any
cause, were considered as events) and overall sur-
vival (death from any cause) were used as endpoints.
Classification of risk was classified according to
groups assigned using the SurvExpress prognostic
index. All survival data were analysed and graphi-
cally presented using GraphPad Prism 6 (Graphpad
Software, CA, USA) with the level of statistical sig-
nature set at p< 0.05.
Results
In consideration of the heterogeneous nature of pros-
tate cancer, we selected cases from our cohort that
were associated with a potential underlying genomic
aberration. Using immunohistochemistry as a prelimi-
nary approach to select for such cases, we selected a
panel of immunohistochemical markers (as described
in Figure 1). These markers, PTEN, MYC, RB1,
TP53, AURKA, AR, are all drivers of aggressive or
advanced disease with associated therapeutics in
development which could aid treatment [27]. Upon
scoring the immunohistochemical expression using
modified Allred scoring criteria, we dichotomized
the expression patterns into high and low categories
(supplementary material, Table S4) [23,28]. Based on
the dichotomized values, we selected 28 ‘simple’
cases, which each represent an associated aberration,
to be examined by high-throughput approaches
(Figure 2). We were able to detect a small number of
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mutations in other known prostate cancer drivers
using the Ampliseq Cancer Hot-spot assay (Ion Tor-
rent) within these 28 patients (supplementary mate-
rial, Figure S1). TP53 mutation is among the highest
in incidence of mutated genes in prostate cancer,
with a mutational burden predominantly observed
in advanced/metastatic cases. In our cohort, three
patients carried TP53 mutations and these were iden-
tified in either PTEN-L (2 patients) or PTEN-M
(1 patient) but not in PTEN-H cases. The overall
incidence of TP53 mutations in our cohort (10%)
was therefore in line with other published studies
[29,30]. Because the mutational incidence was low
overall, these data were not incorporated into the
downstream analysis workflows.
Distinct gene expression profile associated with
PTEN expression
Expression of the tumour suppressor PTEN gene is
reduced in 50–70% of all prostate cancer cases based
on transcript profiling [31–33]. More recently PTEN
downregulation as assessed by IHC has been reported
in 40% of advanced cases and is strongly associated
with reduced median survival. [34] We therefore
chose to assess PTEN expression by IHC as one
potential regulator of cancer progression in grade 7
disease. Loss of PTEN expression at the protein level
was observed in 51% of our cohort when assessed by
immunohistochemistry (Figure 2). This was further
validated at the mRNA level by the whole genome
gene expression assay as well as by single marker
real-time PCR analysis, with observed high concord-
ance between the assays (supplementary material,
Figure S2 and S4). Interestingly, while we observed
differential protein expression for the other six driv-
ers as assessed by IHC, these changes in marker
expression did not correlate with concordant changes
in their transcript expression or with an associated
methylation pattern.
We did not observe any identifiable PTEN somatic
point mutations through high throughput gene-
targeted sequencing (supplementary material, Figure
S1), leading us to hypothesize that there could be
distinguishable subgroups of patients with differing
PTEN status that is based on the level of gene
expression and methylation status of PTEN. To vali-
date this, we performed a bivariate correlation analy-
sis between the gene expression and the methylation
values based on the beta-values (ranging from 0 to
1). The bivariate correlation analysis showed distinct
stratification of the cases into high PTEN expressing
(PTEN-H), moderate PTEN expressing (PTEN-M),
and low PTEN expressing (PTEN-L) subgroups
(p< 0.01) (Figure 3). We then sought to investigate
if these subtypes can be recapitulated by cluster
analysis. By performing unsupervised hierarchical
clustering analysis, the separation of PTEN-H cases
from the PTEN-M and PTEN-L cases was reiterated.
Through cluster analysis, we also observed a distinct
expression profile that distinguished the PTEN-H
cases from the other two subtypes (Figure 4).
Identification of a 35-gene expression signature
associated with prognostic outcome in prostate
cancers
From the cluster analysis of the gene expression data,
we identified a group of 35 genes that was differen-
tially expressed in PTEN-H compared to PTEN-M
and PTEN-L patients in the Northern Ireland gene
expression dataset. We sought to investigate the
prognostic potential of this signature in defining
indolent disease in further cohorts of Gleason 31 4
intermediate risk cases. To do this, we tested the
prognostic ability of the signature in three published
prostate cancer gene expression datasets [20–22]. All
three datasets contain extensive clinico-pathological
features, as well as time to recurrence and time to
death.
Figure 3. Integrated analysis of untreated Gleason 7 (31 4)
prostate tumours revealed distinct subgroups associated with
PTEN status. Bivariate correlation analysis of whole genome
gene expression and methylation data showed the stratification
of three subgroups of cases associated with their PTEN status;
PTEN-H (high PTEN gene expression and low methylation);
PTEN-M (high PTEN gene expression and methylation; PTEN-L
(low PTEN gene expression and high methylation). A positive
correlation between gene expression and methylation status
was observed (R5 0.41, p5 0.03). Cases with low PTEN immu-
nohistochemistry expression status are denoted with ‘L’ next to
each sample case in the correlation plot.
6 CW Ong et al
VC 2018 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res 2018
After retrieving the relevant clinical and pathologi-
cal information, we further limited the survival analy-
sis to Gleason 7 (31 4) cases in each dataset. The
purpose was to eliminate the possibility of Gleason
score being a confounding factor and, furthermore, to
align the clinical features in accordance with the fea-
tures of the Northern Ireland dataset.
We used a risk estimation index based on Cox pro-
portional hazard modelling to determine the prognos-
tic effect of the 35-gene expression signature. We
observed strong survival discrimination in the Taylor
(HR, 6.95; 95% CI, 2.73–17.54; P5 5.97 3 1025)
and Gulzar datasets (HR, 6.40; 95% CI, 2.28–17.96;
P5 4.21 3 1024). To a lower extent, a similar effect
was also observed in the Sboner dataset (HR, 1.77;
95% CI, 1.29–2.41; P5 3.25 3 1024). We also
observed significant differences in survival based on
Kaplan–Meier analysis (Figure 5). We also assessed
the individual prognostic power of each gene within
the signature and found that 4 of the 45 genes were
able individually to provide a HR of 3.21 or greater
with P value of <0.05 (supplementary material,
Table S5).
Discussion
Loss of PTEN is widely recognized as a common
genomic aberration in prostate cancer. Generally, it
has been suggested that PTEN loss occurs more fre-
quently in metastatic prostate cancers than in primary
tumours [20,35]. PTEN loss has previously been
detected in intermediate risk disease and has been
shown by immunohistochemistry to correlate with
recurrence/disease progression. The frequency of loss
of PTEN protein expression examined by immunohis-
tochemistry in our study of intermediate cases (51%)
Figure 4. Unsupervised hierarchical clustering of whole genome gene expression data showing clustering of patient subgroups associ-
ated with PTEN subtypes identified by bivariate analysis. Patient numbers highlighted with the red box are PTEN protein expressing
cases (by immunohistochemistry).
PTEN-associated gene signature prognosticates prostate cancer 7
VC 2018 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res 2018
is therefore consistent with reported findings [20,36].
There are however currently no markers that associ-
ate with PTEN expression and identify patients that
will benefit from active surveillance as opposed to
treatment.
Our purpose in this study was to identify molecular
correlates with PTEN expression and evaluate their
prognostic significance. Through cluster analysis, we
have derived a distinct gene expression profile that
defines a subgroup of PTEN expressing cases. These
PTEN-H cases were marked by the differential
expression of a panel of 35 genes that discriminate
them from the other two subtypes (PTEN-M and
PTEN-L). This geneset profile shows significant prog-
nostic effect across three independent datasets that we
interrogated (HR of 6.95, 6.4, and 1.77, all p< 0.01)
(Figure 5 and supplementary material, Figure S5).
The relationship of these genes to the known prin-
cipal drivers of prostate cancer can be surmised.
Assessing a publicly available dataset [37], we have
determined that only four of the selected genes are
related to androgen receptor activity; FASN, KLK3,
TRPM4, and VIPR1 (supplementary material, Figure
S3). FASN has previously been reported to be a
driver of prostate cancer progression. Analysis of
FASN and VIPR1 individually determined that over-
expression of these genes yields HRs of 0.81 and
0.70, respectively, with a negative correlation with
outcome. Consequently, we ruled out AR activity as
a dominant driving biology for this signature. Subse-
quent analysis focused on the biology of PTEN and,
more specifically, the activation of PTEN (supple-
mentary material, Figure S6). PTEN activity is
known to be regulated in part by phosphorylation.
One key kinase that phosphorylates and activates
PTEN is PKR. PKR is itself activated by high levels
of expression of a subset of mRNAs carrying a
hairpin-loop secondary structure. Within our 35-gene
PTEN-H signature, there are also several components
that suggest a possible role for PKR activation in
mediating PTEN expression, particularly the influ-
ence of TPT1. The TPT1 gene has been previously
shown to be associated with disease progression in
prostate and colorectal cancers [38,39]. Functionally,
TPT1 was reported to be involved in several biologi-
cal processes, including rapamycin signalling as well
as mitosis and nuclear reprogramming [40,41]. Fur-
thermore, gene silencing and knockdown of TPT1
was reported to inhibit cell proliferation and invasion
[38,39]. Notably, it is postulated that the activation
of TPT1 modulates the activity of serine-threonine
kinase PKR [40]. Mounir and colleagues have previ-
ously established the role of PKR in the tumour sup-
pressive activity of PTEN as an alternative link that
is independent of the PI3K signalling pathway [42].
In their study, they reported that the activation of
PKR resulted in the phosphorylation of EIF2 leading
Figure 5. The prognostic value of the 35-gene expression signa-
ture was analysed in three independently published datasets,
GSE21032, GSE16560 and GSE40272 [20–22]. The survival plots
depicted here were derived from Kaplan–Meier analysis (the
P values summarize the differences by the log-rank tests).
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to subsequent inhibition of cell proliferation [42].
Apart from TPT1, actins and tropomycin have also
been described to induce the in-vitro activation of
PKR [43]. Interestingly, within our PTEN-H signa-
ture, there are several representative factors present,
namely TPM2, ACTA2, and ACTG2. These genes
individually have high prognostic effect (significant
hazard risk ratios, Figure 6). Therefore, we propose
that the strong association of genes that are known
PKR activators suggests that our signature of good
outcome is associated biologically with the retention
of PTEN activity and thus the capacity to constrain
or retard the rate of tumour progression. PTEN activ-
ity assessments in restricted sampling of formalin-
fixed material was beyond the technical and feasible
capability of the field and current study design but
will be an important aspect of future validation of
this signature in prospectively sourced samples.
Our investigations yield a gene signature that is
strongly associated with survival outcome in untreated
Gleason 7 (31 4) prostate cancers that could poten-
tially identify high risks patients who would benefit
from early treatment intervention. Currently, bio-
markers evaluated in most studies correlate with grade
and high-risk staging, and are thus possibly con-
founded by tumour proliferation. In our study, we
have essentially excluded that bias and proliferative
component by limiting the analysis to Gleason 7
(31 4) cases. Our signature therefore allows us to fur-
ther postulate that there is limited prospect of progres-
sion for the low risk patients despite pathological
presentation of neoplastic phenotypes and overexpres-
sion of previously reported prognostic markers such as
TPT1. We hypothesize that this is due to the numer-
ous tumour suppressive checkpoints, such as the role
of PKR activity. This implies that some of these genes
may become ‘oncogenic’ or contribute to aggressive
disease once cell cycle checkpoints are compromised.
Without such changes, they are but rather regulators
of normal energy balance or moderators of stress.
In summary, our study to our knowledge is the
first that evaluates markers in a single Gleason score
setting using a comprehensive profiling approach.
Pending further validation, the 35-gene expression
signature derived from this analysis of untreated
Gleason 7 (31 4) prostate cancers has the potential
to accurately stratify patients and provide enhanced
prognostic insights.
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